These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756 [TBL] [Abstract][Full Text] [Related]
4. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
5. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199 [TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
7. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869 [TBL] [Abstract][Full Text] [Related]
8. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Petrucci MT; Avvisati G; La Verde G; De Fabritiis P; Ribersani M; Palumbo G; De Felice L; Rusignuolo A; Simone F; Meloni G; Mandelli F Acta Haematol; 2003; 109(4):184-8. PubMed ID: 12853690 [TBL] [Abstract][Full Text] [Related]
9. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970 [TBL] [Abstract][Full Text] [Related]
10. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Gastineau DA; Litzow MR; Fonseca R; Roy V; Rajkumar SV; Gertz MA Leukemia; 2007 Sep; 21(9):2035-42. PubMed ID: 17581613 [TBL] [Abstract][Full Text] [Related]
11. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. Chang WJ; Kang ES; Lee ST; Kim SH; Kim DW; Kim SJ; Kim K Acta Haematol; 2014; 132(2):226-32. PubMed ID: 24732093 [TBL] [Abstract][Full Text] [Related]
12. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
13. Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure. Pinto V; Castelli A; Gaidano G; Conconi A Am J Hematol; 2010 Jun; 85(6):461-2. PubMed ID: 20513130 [No Abstract] [Full Text] [Related]
14. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064 [TBL] [Abstract][Full Text] [Related]